NASDAQ: CVCapsovision Inc Stock
$5.12-0.55 (-9.7%)
Updated Nov 14, 2025
CV Price
$5.12
Fair Value Price
N/A
Market Cap
$239.84M
52 Week Low
$3.45
52 Week High
$5.72
P/E
N/A
P/B
11.73x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.26
Operating Cash Flow
N/A
Beta
1.41
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CV Overview
Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CV's potential to beat the market
- CV doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
CV
RankedUnranked of 107
RankedUnranked of 107
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.70 | A | |
| $7.35 | A | |
| $32.69 | A |
Be the first to know about important CV news, forecast changes, insider trades & much more!
CV News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CV is poor value based on its book value relative to its share price (11.73x), compared to the US Medical Devices industry average (3.95x)
P/B vs Industry Valuation
CV's short-term assets ($24.05M) exceed its short-term liabilities ($4.64M)
Short-term Liabilities Financials
CV's short-term assets ($24.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more CV due diligence checks available for Premium users.
Valuation
CV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.73x
Industry
3.95x
CV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CV's financial health
Profit margin
Revenue
$3.5M
Net Income
-$7.9M
Profit Margin
-223.9%
Assets to liabilities
Assets
$25.7M
Liabilities
$5.2M
Debt to equity
0.26
CV's short-term assets ($24.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CV's short-term assets ($24.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.7M
Investing
-$12.0k
Financing
$22.4M
CV vs Medical Device Stocks
Capsovision Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.